|
I-DXd Clinical Trials
4 actively recruiting trials across 3 locations
No change since May 2026
Also known as: DS-7300a, Ifinatamab Deruxtecan, Ifinatamab deruxtecan, MK-2400
Pipeline
Phase 2: 1Phase 1/2: 3
Top Sponsors
- Merck Sharp & Dohme LLC4
Indications
- Cancer4
- Lung Cancer2
- Small Cell Lung Cancer Extensive Stage1
- Lung Neoplasm1
- Oesophageal Squamous Cell Carcinoma1
Other1 trial
Santa Rosa, California1 trial
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Providence Medical Foundation ( Site 0124)
Phase 1/2
Lexington, Kentucky1 trial
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
University of Kentucky Chandler Medical Center ( Site 0019)
Phase 2
Pittsburgh, Pennsylvania1 trial
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
UPMC Hillman Cancer Center ( Site 1904)
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.